Phase I trial of CJRB-101 plus pembrolizumab in patients with metastatic non-small cell lung cancer, head and neck squamous cell carcinoma and melanoma
Journal for ImmunoTherapy of Cancer · 2026
DOI: 10.1136/jitc-2025-014702 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2026. Verfasst von Jii Bum Lee und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea (the Republic of). Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea (NRF) funded by the Korea government, CJ Bioscience Company, The Ministry of Food and Drug Safety.
Abstract (Originalsprache)
Background
Dysbiosis of gut microbiome leads to resistance to immunotherapy in various advanced solid tumors. CJRB-101 is a live biotherapeutic product consisting of a novel strain belonging to the species Leuconostoc mesenteroides . To modulate the tumor microenvironment, CJRB-101 was combined with pembrolizumab.
Methods
Preclinical efficacy and mechanistic studies were performed using humanized non-small cell lung cancer (NSCLC) patient-derived xenograft (PDX) models. This is a multicenter, first-in-human, two-part, phase I, open-label study of CJRB-101 (1×10 11 or 4×10 11 colony forming unit (CFU)/day) plus pembrolizumab (200 mg every three weeks (Q3W)) in advanced NSCLC, melanoma, and head and neck squamous cell carcinoma in both immune checkpoint inhibitor (ICI)-naive and ICI-refractory settings. The primary endpoint was to assess the dose-limiting toxicities (DLTs), adverse events, and preliminary activity of the combination treatment. Exploratory endpoints included stool metagenomics analysis and pharmacodynamics parameters.
Results
In four PDX models, CJRB-101 with pembrolizumab demonstrated enhanced antitumor efficacy, showing a tumor growth inhibition (TGI) of 77.3% in the CJRB-101 monotherapy group and 61.9% in the combination group, which was significantly improved compared with pembrolizumab alone. A distinct M2-to-M1 repolarization was observed and validated in vitro. Notably, increased activation of cytotoxic T cells was observed, suggesting an immune-mediated antitumor mechanism of CJRB-101. A total of 42 patients were enrolled in the low-dose cohort (one capsule once a day; n=6) and high-dose cohort (two capsules two times a day, n=36). Metastatic NSCLC accounted for 86% (n=36) and 67% (n=28) of the patients were refractory to ICIs. None of the patients experienced DLT. In ICI-naïve NSCLC (n=12) with programmed death-ligand 1 (PD-L1) >50%, the overall response rate (ORR) and disease control rate (DCR) were 58% and 75%, respectively. The ORR was 5% and DCR was 41% in the ICI-refractory NSCLC (n=22) with an ORR of 5% and DCR of 41%. After a median follow-up of 15.6 months and 8.9 months for ICI-naïve and ICI-refractory NSCLC, the median progression-free survival was 9 months (95% CI 5.6 to not reached) and 1.8 months (95% CI 1.6 to 4.3), respectively. CJRB-101 plus pembrolizumab was well-tolerated, and none of the patients experienced grade > 3 treatment-related adverse events.
Conclusions
Early clinical data show encouraging antitumor response of CJRB-101 plus pembrolizumab in ICI-naïve metastatic NSCLC with PD-L1 > 50%. Trial registration number NCT05877430 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine and Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea (the Republic of).
- Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea (the Republic of).
- Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea (the Republic of).
- CJ Bioscience, Inc, Seoul, Korea (the Republic of).
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Jongno-gu, Seoul, Korea (the Republic of).
- Division of Hematology-Oncology, University of California Irvine School of Medicine, Irvine, California, USA.
Förderung
- National Research Foundation of Korea (NRF) funded by the Korea government
- CJ Bioscience Company
- The Ministry of Food and Drug Safety
Zitieren
APA
Lee, J. B., Baek, S., Kim, D. K., Kwon, B. E., Ahn, J. S., Nagasaka, M., Davar, D., Park, H., Kim, H., Im, J., Yang, J., Yang, E., Shin, G. H., Choi, S., Kwon, J. E., Kim, J. M., Kang, S. Y., Kim, Y., Park, S. Y., …, & Cho, B. C. (2026). Phase I trial of CJRB-101 plus pembrolizumab in patients with metastatic non-small cell lung cancer, head and neck squamous cell carcinoma and melanoma. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-014702
Vancouver
Lee JB, Baek S, Kim DK, Kwon BE, Ahn JS, Nagasaka M, et al. Phase I trial of CJRB-101 plus pembrolizumab in patients with metastatic non-small cell lung cancer, head and neck squamous cell carcinoma and melanoma. Journal for ImmunoTherapy of Cancer. 2026. doi:10.1136/jitc-2025-014702
BibTeX
@article{Lee2026,
author = {Lee, Jii Bum and Baek, Sujeong and Kim, Dong Kwon and Kwon, Bo-Eun and Ahn, Jin Seok and Nagasaka, Misako and Davar, Diwakar and Park, Hyunkyung and Kim, Hyunjeong and Im, Jieun and Yang, Junwon and Yang, Eunchong and Shin, Ga-Hyun and Choi, Soeun and Kwon, Ji-Eun and Kim, Jae-Min and Kang, So-Yeong and Kim, Youngtaek and Park, So Young and Kim, Jae Hwan and Oh, Hyun-Seok and Chalita, Mauricio and Min, Arim and Cho, Byoung Chul},
title = {Phase I trial of CJRB-101 plus pembrolizumab in patients with metastatic non-small cell lung cancer, head and neck squamous cell carcinoma and melanoma},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
doi = {10.1136/jitc-2025-014702}
}
EUVIMED